Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee.

Trial Profile

Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2012

At a glance

  • Drugs Dexibuprofen (Primary) ; Ibuprofen (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Gebro Pharma GmbH
  • Most Recent Events

    • 30 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Planned number of patients changed from 480 to 500 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top